WELLINGTON, New Zealand & KINGSTON, Canada, April 7, 2026
BioOra Limited and Octane Biotech Inc. announced a strategic Letter of Intent (LOI) to expand cell therapy manufacturing using the Cocoon® automated platform, aiming to accelerate the global deployment of CAR-T therapies. The collaboration focuses on scaling manufacturing capacity, improving efficiency, and expanding patient access to advanced cell therapies across Australia, North America, and international markets.
Automated Manufacturing Platform Drives Scalable Cell Therapy
At the center of the collaboration is the Cocoon® automated cell therapy manufacturing platform, a closed, integrated system designed to enable decentralized and scalable production of CAR-T therapies. This technology allows for automated cell processing, reduced contamination risk, and streamlined workflows, addressing one of the most significant challenges in cell therapy commercialization.
The Cocoon platform is already being used to manufacture BioOra’s CD19-targeted CAR-T therapy (Atla-Cel) for patients with relapsed or refractory B-cell lymphoma in New Zealand as part of the ENABLE-2 clinical trial. Building on this success, the collaboration aims to expand production capacity by deploying multiple Cocoon systems within BioOra’s new Christchurch-based manufacturing facility, designed to support high-throughput, GMP-compliant production.
This approach represents a shift toward decentralized manufacturing models, enabling faster delivery of personalized therapies and reducing the vein-to-vein time, a critical factor in improving patient outcomes.
Advertisement
Expanding Global Access to CAR-T Therapies
CAR-T therapies have demonstrated transformative potential in treating hematologic cancers, yet their widespread adoption has been limited by complex manufacturing processes and high costs. The BioOra–Octane collaboration aims to overcome these barriers by developing efficient, scalable production systems that can support regional and global distribution.
The partnership will initially focus on expanding operations in Australia, with plans to extend into North America and other international markets, enabling more patients to access life-saving cell therapies. Additionally, the collaboration will explore the development of new cell therapy programs, further strengthening the pipeline of advanced immunotherapies.
By integrating automated manufacturing with clinical infrastructure, the companies aim to create a more accessible and scalable model for delivering personalized medicine, addressing a critical unmet need in oncology treatment.
Advancing Innovation in Cell Therapy Production
The collaboration also includes the co-development of end-to-end manufacturing solutions, encompassing cell collection, automated processing, and final product release, creating a fully integrated production ecosystem. This innovation is expected to enhance operational efficiency, reduce costs, and improve consistency in therapy production, aligning with the stringent requirements of GMP and regulatory standards.
BioOra’s investment in its Health & Technology Centre in Christchurch further supports the development of a regional hub for advanced cell therapy manufacturing, positioning the company as a leader in the Southern Hemisphere’s CAR-T landscape.
The collaboration highlights the growing importance of automation, digitalization, and advanced bioprocessing technologies in enabling the next generation of regenerative medicine and immuno-oncology therapies.
The partnership between BioOra and Octane Biotech represents a major step forward in scaling CAR-T manufacturing and expanding global access to advanced cell therapies. By leveraging the Cocoon® automated platform and integrated manufacturing solutions, the collaboration aims to overcome key challenges in cell therapy production and delivery, ultimately improving patient access and outcomes.
As demand for personalized cancer treatments continues to rise, innovations in automated manufacturing and decentralized production models will play a critical role in shaping the future of biopharmaceutical and regenerative medicine industries.
Source: BioOra press release
